SciClone Pharmaceuticals (Holdings) Limited Sustainability Profile
SciClone Pharmaceuticals (Holdings) Limited, headquartered in China, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 1995, the company has made significant strides in addressing unmet medical needs, particularly in oncology and infectious diseases. With a strong operational presence in Asia and expanding into global markets, SciClone is renowned for its flagship product, ZADAXIN, a thymosin alpha 1 therapy that enhances immune response. This unique offering positions the company as a leader in immunotherapy, catering to both patients and healthcare providers. SciClone's commitment to research and development, coupled with strategic partnerships, has solidified its market position, making it a key contributor to the advancement of biopharmaceutical solutions. The company continues to focus on delivering high-quality, effective treatments that improve patient outcomes worldwide.
DitchCarbon Score
How does SciClone Pharmaceuticals (Holdings) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SciClone Pharmaceuticals (Holdings) Limited's score of 20 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SciClone Pharmaceuticals (Holdings) Limited's reported carbon emissions
In 2021, SciClone Pharmaceuticals (Holdings) Limited reported total carbon emissions of approximately 111,180 kg CO2e, all of which were classified under Scope 2 emissions. This represents a significant decrease from 2020, when the company recorded total emissions of about 292,800 kg CO2e, also entirely from Scope 2. Despite these figures, SciClone has not established any specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of such commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As of now, there is no data indicating emissions from Scope 1 or Scope 3, and the company has not disclosed any upstream or downstream emissions categories. The emissions data is not cascaded from a parent company, indicating that SciClone Pharmaceuticals operates independently in its reporting. Overall, while the company has made strides in reducing its carbon footprint, further commitments and transparency regarding its climate strategy would enhance its sustainability profile.
How Carbon Intensive is SciClone Pharmaceuticals (Holdings) Limited's Industry?
How Carbon Intensive is SciClone Pharmaceuticals (Holdings) Limited's Location?
SciClone Pharmaceuticals (Holdings) Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SciClone Pharmaceuticals (Holdings) Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
